Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.

@article{Deleu2018SingleAM,
  title={Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.},
  author={Sofie Deleu and Thomas N Kakuda and Kurt Spittaels and Jurgen J Vercauteren and Vera M Hillewaert and Amy Lwin and Lorant Leopold and Richard M. W. Hoetelmans},
  journal={British journal of clinical pharmacology},
  year={2018},
  volume={84 11},
  pages={
          2663-2672
        }
}
AIMS The aim of this study was to evaluate the drug-drug interaction between pimodivir, a novel, non-nucleoside polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A virus polymerase complex, and oseltamivir, to assess the feasibility of this combination therapy. Furthermore, single- and multiple-dose pharmacokinetics and safety of pimodivir in healthy volunteers were assessed. METHODS In Part 1 of this open-label Phase 1 study, healthy volunteers (n = 18) were randomized to… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…